E-mail Print PDF


Röhrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O.
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
J Med Chem. 2015, 58(24):9421-37.

Gfeller D, Zoete V.
Protein homology reveals new targets for bioactive small molecules.
Bioinformatics. 2015, 31(16):2721-7.

Bhuiyan T, Waridel P, Kapuria V, Zoete V, Herr W.
Distinct OGT-Binding Sites Promote HCF-1 Cleavage.
PLoS One. 2015 Aug 25;10(8):e0136636.

Akyuz N, Georgieva ER, Zhou Z, Stolzenberg S, Cuendet MA, Khelashvili G, Altman RB, Terry DS, Freed JH, Weinstein H, Boudker O, Blanchard SC.
Transport domain unlocking sets the uptake rate of an aspartate transporter.
Nature. 2015, 518(7537):68-73.

Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M.
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Proc Natl Acad Sci U S A. 2015, in press

Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Proc Natl Acad Sci USA. 2015, 112(19):6140-5.

Michielin O, Hoeller C.
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Cancer Treat Rev. 2015, 41(8):660-70.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed-Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.
Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients - report of a phase I/IIa clinical trial.
Clin Cancer Res. 2015 Oct 23. pii: clincanres.1212.2015.

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
PLoS One. 2015 Oct 1;10(10):e0139438.

Moura B, Homicsko K, Berthod G, Cerottini JP, Guggisberg D, Gaide O, Maillard MH, Michielin O.
New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities.
Rev Med Suisse. 2015, 11(475):1108, 1110-4


google analytics